Category Research

Novel Malaria Treatment Shows Positive Results for Infants <5kg: Novartis & Medicines for Malaria Venture

Novartis and Medicines for Malaria Venture (MMV) have unveiled encouraging results from their phase II/III CALINA trial, indicating that a newly formulated version of Coartem® (artemether-lumefantrine) tailored for infants weighing under 5kg with malaria demonstrates the necessary pharmacokinetic profile, along…

Read MoreNovel Malaria Treatment Shows Positive Results for Infants <5kg: Novartis & Medicines for Malaria Venture

Jumar Bioincubator Launches Mission: Crafting Australia’s Future CSL with Mini-Brains and Lab-on-a-Chip Wearables

Australia’s Latest Biotech Incubator, Jumar Bioincubator, Unveils First Cohort of Innovative Ventures Melbourne, Australia – Jumar Bioincubator, the newest addition to Australia’s biotech landscape, has officially opened its doors, showcasing 16 pioneering early-stage ventures at its eagerly anticipated Melbourne facility.…

Read MoreJumar Bioincubator Launches Mission: Crafting Australia’s Future CSL with Mini-Brains and Lab-on-a-Chip Wearables

Labcorp Unveils Groundbreaking Blood Test for Early Detection of Neurodegenerative Diseases and Brain Injuries

Labcorp, a leading provider of innovative laboratory services globally, has announced the launch of the nation’s inaugural glial fibrillary acidic protein (GFAP) test. This test serves as a pivotal blood-based biomarker aiding in the early detection of neurodegenerative diseases and…

Read MoreLabcorp Unveils Groundbreaking Blood Test for Early Detection of Neurodegenerative Diseases and Brain Injuries

Dermal Fillers Market 2023-2035: Hyaluronic Acid Innovation Drives Expansion – ResearchAndMarkets.com

Introducing the latest addition to ResearchAndMarkets.com’s offerings, the report on the “Global Dermal Fillers Market, 2023-2035”. Estimated at $3 billion in 2023, the global dermal fillers market is poised for robust growth, projected at a compound annual growth rate (CAGR)…

Read MoreDermal Fillers Market 2023-2035: Hyaluronic Acid Innovation Drives Expansion – ResearchAndMarkets.com

FDA Approves Ipsen’s Onivyde® as Promising First-Line Treatment for Metastatic Pancreatic Adenocarcinoma

Ipsen (Euronext: IPN; ADR: IPSEY) has announced the approval by the U.S. Food and Drug Administration (FDA) of the supplemental new drug application for Onivyde® (irinotecan liposome injection) in combination with oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX) as a first-line therapy…

Read MoreFDA Approves Ipsen’s Onivyde® as Promising First-Line Treatment for Metastatic Pancreatic Adenocarcinoma

U.S. FDA Conducts Inspection of Lupin’s Dabhasa Facility, Finds No Observations

Lupin Limited, a leading global pharmaceutical company, announced today that the United States Food and Drug Administration (U.S. FDA) has successfully completed a Good Manufacturing Practice (GMP) Inspection of its Active Pharmaceutical Ingredient (API) manufacturing facility situated in Dabhasa, India.…

Read MoreU.S. FDA Conducts Inspection of Lupin’s Dabhasa Facility, Finds No Observations